Safe drug use in patients with cirrhosis
Boletín de Información Farmacoterapéutica de Navarra · 2023
DOI: 10.54095/bitn20233102en ↗Kurz gefasst
Fachartikel in der Zeitschrift Boletín de Información Farmacoterapéutica de Navarra, 2023. Verfasst von Andrea Rodríguez Esquíroz.
Abstract (Originalsprache)
Cirrhosis is the fibrosis of the liver as a result of different liver damage mechanisms that leads to the inflammation and generation of scar tissue, thus producing nodules. Liver cirrhosis affects both drug pharmacokinetics and pharmacodynamics, and must therefore be taken into consideration when prescribing. The severity and prognosis of cirrhosis are measured using the Child-Pugh classification. The aim of this bulletin is to help with selection of the most appropriate therapeutic alternative for patients with cirrhosis by providing a series of safety and dose-adjustment guidelines for the drugs most commonly prescribed in primary healthcare.
Zitieren
APA
Esquíroz, A. R. (2023). Safe drug use in patients with cirrhosis. Boletín de Información Farmacoterapéutica de Navarra. https://doi.org/10.54095/bitn20233102en
Vancouver
Esquíroz AR. Safe drug use in patients with cirrhosis. Boletín de Información Farmacoterapéutica de Navarra. 2023. doi:10.54095/bitn20233102en
BibTeX
@article{Esquroz2023,
author = {Esquíroz, Andrea Rodríguez},
title = {Safe drug use in patients with cirrhosis},
journal = {Boletín de Información Farmacoterapéutica de Navarra},
year = {2023},
doi = {10.54095/bitn20233102en}
}
EUVIMED